The present invention relates to highly active glycoproteins with specificsialylation degrees, a pharmaceutical composition for use in diagnosis ortherapy comprising the glycoproteins, a method for the determination of highlyactive glycoproteins and of the conditions for their production, a method forproducing the highly active glycoproteins, and a method for differentialsialylation of secretory glycoproteins. The invention also relates to the useof the recombinantly expressed highly active glycoproteins for biologicalpurposes and for prophylactic and/or therapeutic treatment or diagnosis ofdiseases, particularly bone marrow transplantation, neutropenia, cytopenia,AML and myelodysplastic syndromes, cancer, HIV and/or diseases ofhematopoietic systems.
